SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Yuan Wang, Ping Yan, Zhentao Liu, Xiaodan Yang, Yaping Wang, Zhirong Shen, Hua Bai, Jie Wang, Zhijie Wang, MEK inhibitor can reverse the resistance to bevacizumab in A549 cells harboring Kirsten rat sarcoma oncogene homolog mutation, Thoracic Cancer, 2016, 7, 1
  2. 2
    Mary Rusckowski, Yuzhen Wang, Francis G. Blankenberg, Zoia Levashova, Marina V. Backer, Joseph M. Backer, Targeted scVEGF/177Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy, EJNMMI Research, 2016, 6, 1

    CrossRef

  3. 3
    Ace J. Hatch, Jeffrey M. Clarke, Andrew B. Nixon, Herbert I. Hurwitz, Identifying Blood-Based Protein Biomarkers for Antiangiogenic Agents in the Clinic, The Cancer Journal, 2015, 21, 4, 322

    CrossRef

  4. 4
    Richard F. Spaide, Optical Coherence Tomography Angiography Signs of Vascular Abnormalization With Antiangiogenic Therapy for Choroidal Neovascularization, American Journal of Ophthalmology, 2015, 160, 1, 6

    CrossRef

  5. 5
    Il-Kyu Choi, Hyewon Shin, Eonju Oh, Ji Young Yoo, June Kyu Hwang, Kyungsub Shin, De-Chao Yu, Chae-Ok Yun, Potent and long-term antiangiogenic efficacy mediated by FP3-expressing oncolytic adenovirus, International Journal of Cancer, 2015, 137, 9
  6. 6
    Angelos Koutras, Vasiliki Kotoula, George Fountzilas, Prognostic and predictive role of vascular endothelial growth factor polymorphisms in breast cancer, Pharmacogenomics, 2015, 16, 1, 79

    CrossRef

  7. 7
    M. Tsagkataki, T. Papathomas, D. Lythgoe, A. Kamal, Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion, Seminars in Ophthalmology, 2015, 30, 5-6, 352

    CrossRef

  8. 8
    Richard T. Penson, Kathleen M. Moore, Gini F. Fleming, Patricia Braly, Veronica Schimp, Hoa Nguyen, Ursula A. Matulonis, Susana Banerjee, Paul Haluska, Martin Gore, Diane C. Bodurka, Rebecca R. Hozak, Adarsh Joshi, Yihuan Xu, Jonathan D. Schwartz, William P. McGuire, A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma, Gynecologic Oncology, 2014, 134, 3, 478

    CrossRef

  9. 9
    Cristiano Ferrario, Gerald Batist, Advances in the approach to novel drug clinical development for breast cancer, Expert Opinion on Drug Discovery, 2014, 9, 6, 647

    CrossRef

  10. 10
    Fahimeh Ghavamipour, S. Shirin Shahangian, Reza H. Sajedi, S. Shahriar Arab, Kamran Mansouri, Mahmoud Reza Aghamaali, Development of a highly-potent anti-angiogenic VEGF8–109 heterodimer by directed blocking of its VEGFR-2 binding site, FEBS Journal, 2014, 281, 19
  11. 11
    I. Pastushenko, P.B. Vermeulen, G.G. Van den Eynden, A. Rutten, F.J. Carapeto, L.Y. Dirix, S. Van Laere, Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications, British Journal of Dermatology, 2014, 171, 2
  12. 12
    Tetsuro Ohba, Justin M.M. Cates, Heather A. Cole, David A. Slosky, Hirotaka Haro, Jiro Ichikawa, Takashi Ando, Herbert S. Schwartz, Jonathan G. Schoenecker, Pleiotropic effects of bisphosphonates on osteosarcoma, Bone, 2014, 63, 110

    CrossRef

  13. 13
    Marco Bartolotti, Enrico Franceschi, Rosalba Poggi, Alicia Tosoni, Monica Di Battista, Alba A Brandes, Resistance to antiangiogenic therapies, Future Oncology, 2014, 10, 8, 1417

    CrossRef

  14. 14
    A J C Pommier, R Shaw, S K M Spencer, S R Morgan, P M Hoff, J D Robertson, S T Barry, J M Jürgensmeier, Serum protein profiling reveals baseline and pharmacodynamic biomarker signatures associated with clinical outcome in mCRC patients treated with chemotherapy ± cediranib, British Journal of Cancer, 2014, 111, 8, 1590

    CrossRef

  15. 15
    L G M Daenen, J M Houthuijzen, G A Cirkel, J M L Roodhart, Y Shaked, E E Voest, Treatment-induced host-mediated mechanisms reducing the efficacy of antitumor therapies, Oncogene, 2014, 33, 11, 1341

    CrossRef

  16. 16
    Toyonori Tsuzuki, Naoto Sassa, Yoshie Shimoyama, Takamitsu Morikawa, Ryoichi Shiroki, Makoto Kuroda, Akitoshi Fukatsu, Kyoko Kuwahara, Yasushi Yoshino, Ryohei Hattori, Momokazu Gotoh, Tyrosine kinase inhibitor-induced vasculopathy in clear cell renal cell carcinoma: an unrecognized antitumour mechanism, Histopathology, 2014, 64, 4
  17. 17
    A. Favia, M. Desideri, G. Gambara, A. D'Alessio, M. Ruas, B. Esposito, D. Del Bufalo, J. Parrington, E. Ziparo, F. Palombi, A. Galione, A. Filippini, VEGF-induced neoangiogenesis is mediated by NAADP and two-pore channel-2-dependent Ca2+ signaling, Proceedings of the National Academy of Sciences, 2014, 111, 44, E4706

    CrossRef

  18. 18
    Lindsay S. Cooley, Andreas Bikfalvi, Reference Module in Biomedical Sciences, 2014,

    CrossRef

  19. 19
    Madon M. Maile, Evelyn Y.T. Wong, Daphne Suzin, Nicole E. Birrer, Richard T. Penson, Anti-Angiogenesis Drug Discovery and Development, 2014,

    CrossRef

  20. 20
    Gi Kim, Oug Cheong, Song Bae, Jongheon Shin, Sang Lee, 6″-Debromohamacanthin A, a Bis (Indole) Alkaloid, Inhibits Angiogenesis by Targeting the VEGFR2-Mediated PI3K/AKT/mTOR Signaling Pathways, Marine Drugs, 2013, 11, 4, 1087

    CrossRef

  21. 21
    K Danza, B Pilato, R Lacalamita, T Addati, F Giotta, A Bruno, A Paradiso, S Tommasi, Angiogenetic axis angiopoietins/Tie2 and VEGF in familial breast cancer, European Journal of Human Genetics, 2013, 21, 8, 824

    CrossRef